IDEAYA Biosciences IncNASDAQ:IDYA
- LAST PRICE37.8700
- TODAY'S CHANGE (%)-1.9800 (-4.9686%)
- Bid / Lots37.8500/ 2
- Ask / Lots37.9200/ 1
- Open / Previous Close39.0600 / 39.8500
- Day Range
- 52 Week Range
- Volume119,391
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IDYA |
|---|---|---|
| 09:32 ET | 2624 | 39.18 |
| 09:34 ET | 1200 | 38.875 |
| 09:36 ET | 7679 | 38.92 |
| 09:38 ET | 300 | 38.79 |
| 09:39 ET | 1000 | 38.5 |
| 09:41 ET | 427 | 38.23 |
| 09:43 ET | 1255 | 38.535 |
| 09:45 ET | 100 | 38.53 |
| 09:48 ET | 100 | 38.435 |
| 09:50 ET | 300 | 38.34 |
| 09:52 ET | 1200 | 38.43 |
| 09:54 ET | 2826 | 38.64 |
| 09:56 ET | 1406 | 38.32 |
| 09:57 ET | 500 | 38.35 |
| 09:59 ET | 400 | 38.5 |
| 10:01 ET | 200 | 38.3 |
| 10:03 ET | 200 | 38.36 |
| 10:06 ET | 500 | 38.38 |
| 10:08 ET | 500 | 38.47 |
| 10:10 ET | 400 | 38.57 |
| 10:12 ET | 200 | 38.7 |
| 10:14 ET | 300 | 38.64 |
| 10:17 ET | 100 | 38.62 |
| 10:19 ET | 1200 | 38.67 |
| 10:21 ET | 862 | 38.57 |
| 10:24 ET | 3305 | 38.58 |
| 10:26 ET | 100 | 38.64 |
| 10:28 ET | 200 | 38.665 |
| 10:30 ET | 1200 | 38.75 |
| 10:32 ET | 600 | 38.68 |
| 10:33 ET | 500 | 38.48 |
| 10:35 ET | 800 | 38.38 |
| 10:37 ET | 400 | 38.2 |
| 10:39 ET | 1300 | 38.12 |
| 10:42 ET | 1600 | 38.02 |
| 10:44 ET | 2000 | 38.16 |
| 10:48 ET | 200 | 38.315 |
| 10:50 ET | 483 | 38.23 |
| 10:51 ET | 100 | 38.23 |
| 10:53 ET | 1605 | 38.265 |
| 10:57 ET | 200 | 38.24 |
| 11:00 ET | 700 | 38.27 |
| 11:02 ET | 4100 | 38.195 |
| 11:04 ET | 900 | 38.19 |
| 11:06 ET | 5197 | 38.105 |
| 11:08 ET | 200 | 38.11 |
| 11:09 ET | 400 | 38.11 |
| 11:11 ET | 1187 | 38.245 |
| 11:13 ET | 100 | 38.21 |
| 11:15 ET | 400 | 38.305 |
| 11:18 ET | 525 | 38.235 |
| 11:20 ET | 400 | 38.14 |
| 11:22 ET | 100 | 38.19 |
| 11:24 ET | 600 | 38.235 |
| 11:26 ET | 100 | 38.23 |
| 11:31 ET | 343 | 38.17 |
| 11:33 ET | 1100 | 38 |
| 11:36 ET | 300 | 38 |
| 11:38 ET | 700 | 37.93 |
| 11:42 ET | 200 | 37.96 |
| 11:44 ET | 200 | 37.95 |
| 11:47 ET | 100 | 38.02 |
| 11:49 ET | 500 | 38.01 |
| 11:51 ET | 100 | 37.99 |
| 11:54 ET | 1000 | 37.95 |
| 11:56 ET | 100 | 38.025 |
| 11:58 ET | 100 | 37.96 |
| 12:00 ET | 335 | 38.0004 |
| 12:03 ET | 738 | 37.95 |
| 12:05 ET | 1200 | 38.01 |
| 12:07 ET | 100 | 38.025 |
| 12:12 ET | 900 | 38.02 |
| 12:14 ET | 200 | 37.99 |
| 12:16 ET | 105 | 38.01 |
| 12:18 ET | 273 | 37.975 |
| 12:21 ET | 1100 | 37.89 |
| 12:23 ET | 900 | 37.89 |
| 12:25 ET | 189 | 37.87 |
Yesterday
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study, from 10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
10:05AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 22, 2024
Apr 5, 2024
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 6:00AM ET on Friday Apr 05, 2024 by Dow Jones
6:00AM ET on Friday Apr 05, 2024 by Dow Jones
Apr 1, 2024
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event, from 6:00AM ET on Monday Apr 01, 2024 by Dow Jones
6:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IDEAYA Biosciences Inc | 3.0B | -19.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.6x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.2B | -8.6x | --- |
Apogee Therapeutics Inc | 2.7B | -26.7x | --- |
MoonLake Immunotherapeutics | 2.7B | -54.7x | --- |
Company Information
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Contact Information
- Headquarters
- 7000 Shoreline Ct Ste 350SOUTH SAN FRANCISCO, CA, United States 94080-7604
- Phone
- 650-443-6209
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Timothy Shannon
- President, Chief Executive Officer, Director
- Yujiro Hata
- Senior Vice President, Principal Accounting Officer, Head - Finance and Investor Relations
- Andres Briseno
- Chief Scientific Officer
- Michael White
- Vice President, Head of Clinical Oncology and Medical Affairs
- Matthew Maurer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
|---|---|
Revenue (TTM) | $23.4M |
Shares Outstanding | 74.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.83 |
EPS | $-1.96 |
Book Value | $9.55 |
P/E Ratio | -19.3x |
Price/Sales (TTM) | 127.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -574.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
